FAM
ALXN

Flaharty Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Flaharty Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,051
Closed -$560K – 141
2021
Q2 		$560K Sell
3,051
-67
-2% -$11.5K 0.12% 67
2021
Q1 		$477K Sell
3,118
-21,401
-87% -$3.31M 0.11% 71
2020
Q4 		$3.83M Sell
24,519
-2,788
-10% -$358K 0.96% 23
2020
Q3 		$3.13M Hold
27,307
– – 0.98% 21
2020
Q2 		$3.06M Hold
27,307
– – 1.08% 21
2020
Q1 		$2.45M Buy
27,307
+2,194
+9% +$215K 1.13% 18
2019
Q4 		$2.72M Sell
25,113
-2,000
-7% -$214K 0.96% 18
2019
Q3 		$2.65M Hold
27,113
– – 1.01% 18
2019
Q2 		$3.55M Sell
27,113
-4
-0% -$516 1.38% 19
2019
Q1 		$3.67M Sell
27,117
-1,000
-4% -$124K 1.47% 18
2018
Q4 		$2.74M Hold
28,117
– – 1.17% 20
2018
Q3 		$3.85M Sell
28,117
-31
-0.1% -$3.89K 1.5% 19
2018
Q2 		$3.5M Sell
28,148
-1,500
-5% -$175K 1.36% 20
2018
Q1 		$3.22M Sell
29,648
-1,500
-5% -$179K 1.36% 20
2017
Q4 		$3.73M Sell
31,148
-250
-0.8% -$30.4K 1.63% 19
2017
Q3 		$4.43M Buy
31,398
+31,367
+101,184% +$4.26M 2.28% 17
2017
Q2 		$3.89K Sell
31
-31,367
-100% -$3.65M 2.18% 17
2017
Q1 		$3.65M Buy
+31,398
New +$4.05M 2.29% 17

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Flaharty Asset Management's ALXN Position: Q3 2021 in Review

Flaharty Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,051 shares — an estimated $560K sold.

Flaharty Asset Management first reported a position in ALXN in Q1 2017 and held it in 18 quarters. The position peaked at $4.43M in Q3 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Flaharty Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Flaharty Asset Management sold 3,051 Alexion Pharmaceuticals shares in Q3 2021, an estimated $560K.
  • Flaharty Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 18 quarters.
  • Flaharty Asset Management's Alexion Pharmaceuticals position peaked at $4.43M in Q3 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Flaharty Asset Management's 13F filing for Q3 2021, filed 2 Nov 2021.